

[Asparaginase](#)

Statut de médicament essentiel

Section:

[8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.1. Cytotoxic medicines](#)

Codes ATC: [L01XX02](#)

EMLc

Indication

Lymphoid leukaemia, not elsewhere classified Code ICD11: [2B33.3](#)

Type de médicament

Biological agent

Type de liste

Liste de base

Formulations

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Historique des statuts LME

Ajouté pour la première fois en 2015 ([TRS 994](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Balises

Biological

Wikipédia

[Asparaginase](#)

DrugBank

[Asparaginase](#)

Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.